360 related articles for article (PubMed ID: 38473281)
21. Signaling of Tumor-Derived sEV Impacts Melanoma Progression.
Zebrowska A; Widlak P; Whiteside T; Pietrowska M
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32709086
[TBL] [Abstract][Full Text] [Related]
22. STIM1-regulated exosomal EBV-LMP1 empowers endothelial cells with an aggressive phenotype by activating the Akt/ERK pathway in nasopharyngeal carcinoma.
Deng Y; Liu X; Huang Y; Ye J; He Q; Luo Y; Chen Y; Li Q; Lin Y; Liang R; Li Y; Wei J; Zhang J
Cell Oncol (Dordr); 2023 Aug; 46(4):987-1000. PubMed ID: 36917356
[TBL] [Abstract][Full Text] [Related]
23. Exosomes: Critical Mediators of Tumour Microenvironment Reprogramming.
Malla RR; Shailender G; Kamal MA
Curr Med Chem; 2021; 28(39):8182-8202. PubMed ID: 33334279
[TBL] [Abstract][Full Text] [Related]
24. Evaluating tumor cell- and T cell-derived extracellular vesicles as potential biomarkers of cancer and immune cell competence.
Whiteside TL
Expert Rev Mol Diagn; 2023 Feb; 23(2):109-122. PubMed ID: 36787282
[TBL] [Abstract][Full Text] [Related]
25. Tumor-Derived Exosomes in Tumor-Induced Immune Suppression.
Hao Q; Wu Y; Wu Y; Wang P; Vadgama JV
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163380
[TBL] [Abstract][Full Text] [Related]
26. Tumor-Derived Exosomes (TEX) and Their Role in Immuno-Oncology.
Whiteside TL; Diergaarde B; Hong CS
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207762
[TBL] [Abstract][Full Text] [Related]
27. The Dichotomy of Tumor Exosomes (TEX) in Cancer Immunity: Is It All in the ConTEXt?
Kunigelis KE; Graner MW
Vaccines (Basel); 2015 Dec; 3(4):1019-51. PubMed ID: 26694473
[TBL] [Abstract][Full Text] [Related]
28. Drug-resistant endothelial cells facilitate progression, EMT and chemoresistance in nasopharyngeal carcinoma via exosomes.
Huang L; Hu C; Chao H; Zhang Y; Li Y; Hou J; Xu Z; Lu H; Li H; Chen H
Cell Signal; 2019 Nov; 63():109385. PubMed ID: 31394194
[TBL] [Abstract][Full Text] [Related]
29. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.
Hu S; Ma J; Su C; Chen Y; Shu Y; Qi Z; Zhang B; Shi G; Zhang Y; Zhang Y; Huang A; Kuang Y; Cheng P
Acta Biomater; 2021 Nov; 135():567-581. PubMed ID: 34506976
[TBL] [Abstract][Full Text] [Related]
30. The potential role of tumor-derived exosomes in diagnosis, prognosis, and response to therapy in cancer.
Czystowska-Kuzmicz M; Whiteside TL
Expert Opin Biol Ther; 2021 Feb; 21(2):241-258. PubMed ID: 32813990
[TBL] [Abstract][Full Text] [Related]
31. Combinations of radiotherapy with immunotherapy in nasopharyngeal carcinoma.
Yang X; Ren H; Li Z; Peng X; Fu J
Int Immunopharmacol; 2023 Dec; 125(Pt A):111094. PubMed ID: 37871379
[TBL] [Abstract][Full Text] [Related]
32. Exosome nanovesicles as potential biomarkers and immune checkpoint signaling modulators in lung cancer microenvironment: recent advances and emerging concepts.
Khan NA; Asim M; Biswas KH; Alansari AN; Saman H; Sarwar MZ; Osmonaliev K; Uddin S
J Exp Clin Cancer Res; 2023 Aug; 42(1):221. PubMed ID: 37641132
[TBL] [Abstract][Full Text] [Related]
33. Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma.
Renaud S; Lefebvre A; Mordon S; Moralès O; Delhem N
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560253
[TBL] [Abstract][Full Text] [Related]
34. Protein cargo in extracellular vesicles as the key mediator in the progression of cancer.
Hánělová K; Raudenská M; Masařík M; Balvan J
Cell Commun Signal; 2024 Jan; 22(1):25. PubMed ID: 38200509
[TBL] [Abstract][Full Text] [Related]
35. Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment.
Whiteside TL
Semin Immunol; 2018 Feb; 35():69-79. PubMed ID: 29289420
[TBL] [Abstract][Full Text] [Related]
36. Cancer associated-fibroblast-derived exosomes in cancer progression.
Li C; Teixeira AF; Zhu HJ; Ten Dijke P
Mol Cancer; 2021 Dec; 20(1):154. PubMed ID: 34852849
[TBL] [Abstract][Full Text] [Related]
37. Identification of prognostic biomarkers for response to radiotherapy by DNA microarray in nasopharyngeal carcinoma patients.
Yang S; Chen J; Guo Y; Lin H; Zhang Z; Feng G; Hao Y; Cheng J; Liang P; Chen K; Wu H; Li Y
Int J Oncol; 2012 May; 40(5):1590-600. PubMed ID: 22267178
[TBL] [Abstract][Full Text] [Related]
38. An immune-related prognostic model predicts neoplasm-immunity interactions for metastatic nasopharyngeal carcinoma.
Chen X; Ding Q; Lin T; Sun Y; Huang Z; Li Y; Hong W; Chen X; Wang D; Qiu S
Front Immunol; 2023; 14():1109503. PubMed ID: 37063853
[TBL] [Abstract][Full Text] [Related]
39. Revealing the crosstalk between nasopharyngeal carcinoma and immune cells in the tumor microenvironment.
Jiang J; Ying H
J Exp Clin Cancer Res; 2022 Aug; 41(1):244. PubMed ID: 35964134
[TBL] [Abstract][Full Text] [Related]
40. Metabolic Reprogramming and Immune Evasion in Nasopharyngeal Carcinoma.
Huang H; Li S; Tang Q; Zhu G
Front Immunol; 2021; 12():680955. PubMed ID: 34566954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
